Clinical trialsCompany release
Lexeo starts pivotal SUNRISE-FA 2 trial of LX2006 in Friedreich ataxia cardiomyopathy
🇺🇸 Lexeo Therapeutics, Inc. (LXEO) · Mon 16 Nov 2026
The US gene therapy developer expects topline data in the second half of 2027 and says a BLA could be filed in the first half of 2028.
Lexeo Therapeutics says its pivotal SUNRISE-FA 2 study of the gene therapy LX2006 in Friedreich ataxia cardiomyopathy began in June 2026. The information comes from the company's corporate presentation, which cites its 10-Q quarterly filing of 12 August 2026.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): Lexeo Therapeutics, Inc. ↗
Article written by VigiEye from the official source (Lexeo Therapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.
More Clinical trials
All →
Cerenome reports no dose-limiting toxicities in first 10 patients on repeat intraventricular REYOBIQ
🇺🇸 Cerenome, Inc. (CNSY) · Mon 16 Nov 2026
Clearmind completes Part C enrolment in CMND-100 alcohol use disorder trial
Clearmind Medicine Inc. (CMND) · Mon 16 Nov 2026
Jasper Therapeutics completes IgAN cohort enrolment as Kira deal closes and cash reaches $135.3M
🇺🇸 Jasper Therapeutics, Inc. (JSPR) · Mon 16 Nov 2026
CG Oncology's cretostimogene meets Phase 3 PIVOT-006 endpoint in intermediate-risk bladder cancer
🇺🇸 CG Oncology, Inc. (CGON) · Mon 16 Nov 2026
Aptevo's mipletamig triplet yields 79% CR/CRi in TP53-mutated AML; infusion reactions fall
🇺🇸 Aptevo Therapeutics Inc. (APVO) · Mon 16 Nov 2026
Rein Therapeutics releases blinded Phase 2 RENEW lung function data for inhaled LTI-03 in IPF
🇺🇸 Rein Therapeutics, Inc. (RNTX) · Mon 16 Nov 2026